Anúncio
relacionado a: esquemic colorectal cancer and brain metastasis pdfFrequent Questions For Physicians About Colorectal Cancer. HER2+ mCRC Treatment Option. Learn About An FDA-Approved Treatment Option For HER2+ Metastatic Colorectal Cancer.
Resultado da Busca
21 de fev. de 2021 · Brain metastases (BM) from colorectal cancer (CRC) are rare. There is little available information regarding incidence, risk factors, prognostic factors, treatment, and overall survival (OS). In this systematic review we performed a research of the current literature and exposed an average incidence of 2.10%.
- Sophie Müller, Franziska Köhler, Anne Hendricks, Carolin Kastner, Kevin Börner, Johannes Diers, Joha...
- 10.3390/cancers13040900
- 2021
- Cancers (Basel). 2021 Feb; 13(4): 900.
- Purpose
- Conclusion
- Parameters assessed
- Conclusion
- Data availability Not applicable.
- Declarations
Brain metastasis (BM) in colorectal cancer patients is rare and is associated with dismal outcomes. Our study aims to evaluate the incidence and predictors of BM in patients with colorectal cancer.
Our study supports the low incidence of brain metastasis in patients with colorectal cancer. A unique set of characteristics is identified to confer an increased risk of brain metastases. Keywords Brain metastasis · Predictors · Colorectal cancer · Incidence
We investigated variables from these patients include sex, age, race, ethnicity, population density, income, primary cancer site, CRC tumor grade, histological type, tumor size, regional lymph node involvement, and extracranial meta-static sites. Outcome measures were incidence and predic-tors of BM in colorectal cancer patients.
Colorectal cancer leading to brain metastasis is associated with high rates of mortality and poor prognosis. This study identified certain clinical characteristics that may predict the occurrence of BM, which may lead to earlier detection and diagnosis. We found the rate of BM to develop from CRC to be 0.30%. We recommend a supplemental study that ...
Code availability Surveillance, Epidemiology, and End Results Pro-gram (SEER) Data.
Competing interests The authors declare no competing interests.
- Elishia Thompson, Shoujit Banerjee, Sierra Thompson, Ryan Silva, Andrew Muse, Hina Arif-Tiwari, Aron...
- 2021
Background: More than 50% of colorectal cancer (CRC) patients will develop metastatic disease. Brain metastasis (BM) from colorectal cancer is uncommon (0.6-1.36%). This study aims to investigate the patient characteristics, treatment modalities and prognostic factors in this rare population.
- Zhaohui Jin, William Breen, Rui Jin, Paul D. Brown, Joleen Marie Hubbard
- 2020
Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival. Method:
- Troels Dreier Christensen, Karen-Lise Garm Spindler, Jesper Andreas Palshof, Dorte Lisbet Nielsen
- 2016
22 de jan. de 2021 · In this study, we investigated the impact of different treatments for colorectal cancer patients with brain metastases. Methods: We identified stage 4 colorectal adenocarcinoma patients with brain metastasis using the National Cancer Database diagnosed between 2010 and 2015.
- Suleyman Yasin Goksu, Muhammad Shaalan Beg, Aravind Sanjeevaiah, Emrah Gumusgoz, David Hsieh, Muhamm...
- 2021
21 de fev. de 2021 · Brain Metastases from Colorectal Cancer: A Systematic Review of the Literature and Meta-Analysis to Establish a Guideline for Daily Treatment. February 2021. Cancers 13 (4):900. DOI:...
10 de out. de 2022 · To investigate the clinical characteristics, survival, prognostic factors, and treatment of brain metastasis (BM) from colorectal cancer (CRC). Twenty-one patients with BM from CRC were retrospectively reviewed.
